Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: A randomized controlled trial. The ADDITION-Europe study

Diabetes Care

Volumn 37, Issue 7, 2014, Pages 2015-2023

  Sandbæk, Annelli ^a   Griffin, Simon J ^b   Sharp, Stephen J ^b   Simmons, Rebecca K ^b   Borch Johnsen, Knut ^c,d   Rutten, Guy E H M ^e   Van Den Donk, Maureen ^e   Wareham, Nicholas J ^b   Lauritzen, Torsten ^a   Davies, Melanie J ^f   Khunti, Kamlesh ^f  

^a AARHUS UNIVERSITY   (Denmark)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c STENO DIABETES CENTER   (Denmark)

^d HOLBÆK HOSPITAL   (Denmark)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DENMARK; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTENSIVE CARE; INTERMETHOD COMPARISON; KIDNEY DISEASE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ROUTINE CARE; SCREENING TEST; THERAPY EFFECT; UNITED KINGDOM; CLINICAL TRIAL; CLUSTER ANALYSIS; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; EPIDEMIOLOGY; GENERAL PRACTICE; MASS SCREENING; PRIMARY HEALTH CARE; PROCEDURES; SECONDARY PREVENTION;

ADULT; AGED; CLUSTER ANALYSIS; DENMARK; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PRIMARY HEALTH CARE; QUESTIONNAIRES; SECONDARY PREVENTION;

EID: 84903517020     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1544     Document Type: Article

References (32)

1. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)
2. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-163 (Pubitemid 32156199)
3. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232 (Pubitemid 35463925)
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet 1999;354:602]. Lancet 1998;352:837-853
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)
6. Olivarius NF, Beck-Nielsen H, Andreasen AH, HørderM, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323:970-975 (Pubitemid 33016046)
7. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007;335:486
8. Griffin SJ, Borch-Johnsen K, Davies MJ, et al.; Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011;378:156-167
9. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572 (Pubitemid 351831357)
10. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
11. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
12. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
13. Alberti KG, Zimmet PZ. De finition, diagnosis and classi fication of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553 (Pubitemid 28319935)
14. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G; Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000;24(Suppl. 3):S6-S11
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
16. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ 1999;318:29]. BMJ 1998;317:703-713
17. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular andmicrovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
18. Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published correction appears in Diabetes Care 1997;20:1048]. Diabetes Care 1997;20:614-620 (Pubitemid 27143424)
19. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016
20. McIntosh A, Hutcchinson A, Home PD; Royal College of General Practitioners. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose. Sheffield, U.K., University of Sheffield, 2001
21. Danish College of General Practitioners. Non Insulin Dependent Diabetes Mellitus - NIDDM. A Practical Guideline. Copenhagen, Danish College of General Practitioners, 1999
22. Rutten GEHM, Verhoeven S, Heine RJ, et al. NHG-standaard diabetes mellitus type 2 (eerste herziening). HuisartsWet 1999;42:67-84 [inDutch]
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
24. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(Suppl.):823-833
25. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289 (Pubitemid 24324972)
26. Wu EQ, Borton J, Said G, et al. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007;23:2035-2042 (Pubitemid 350246591)
27. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med 2005;24:993-1007 (Pubitemid 40426000)
28. Sandbaek A, Griffin SJ, Rutten G, et al. Stepwise screening for diabetes identi fies people with high butmodifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51:1127-1134
29. HermanWH, Pop-Busui R, Braffett BH, et al.; DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med 2012;29:937-944
30. Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med 2003;20:368-374 (Pubitemid 36605621)
31. Campbell MK, Fayers PM, Grimshaw JM. Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research. Clin Trials 2005;2:99-107 (Pubitemid 40637892)
32. CONSORT. Sample size: item 7a - how sample sizewas determined [article online], 2010. Available from http://www.consort-statement.org/consortstatement/ 3-12-methods/item7a-sample-size. Accessed 5 April 2014